HistoIndex Secures SGD9M in Funding for Imaging Solutions
HistoIndex, a company based in Singapore that specializes in developing imaging solutions for biological tissues, has successfully raised SGD9 million in funding.
This funding round was led by OCBC and saw participation from ZIG Ventures and SEEDS Capital, showcasing confidence in the company’s innovative approach.
The primary objective of the funding is to support HistoIndex in expanding its operations and furthering its research and development efforts.
Established in 2010 and helmed by CEO Dr. Gideon Ho, HistoIndex is at the forefront of providing stain-free and automated imaging solutions for the visualization and quantification of fibrosis in biological tissues. By leveraging biophotonic technology and AI-driven analysis, the company offers cutting-edge tools that enhance the assessment of fibrosis changes and drug effectiveness.
These digital pathology solutions play a crucial role in expediting clinical research, accelerating pharmaceutical drug development, and setting new standards in medical diagnostics.
Recently, HistoIndex introduced its first laboratory developed test (LDT) called FibroSIGHT, which is now available for ordering in the US. This innovative test is specifically designed to empower clinicians with accurate liver fibrosis assessment, marking a significant milestone for the company.
Conclusion
With this latest funding injection, HistoIndex is poised to drive further advancements in the field of biological tissue imaging and solidify its position as a leader in the industry.
FinSMEs
05/05/2025
